Correlation Between Unicycive Therapeutics and First Wave

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Unicycive Therapeutics and First Wave at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Unicycive Therapeutics and First Wave into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Unicycive Therapeutics and First Wave BioPharma, you can compare the effects of market volatilities on Unicycive Therapeutics and First Wave and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Unicycive Therapeutics with a short position of First Wave. Check out your portfolio center. Please also check ongoing floating volatility patterns of Unicycive Therapeutics and First Wave.

Diversification Opportunities for Unicycive Therapeutics and First Wave

0.0
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Unicycive and First is 0.0. Overlapping area represents the amount of risk that can be diversified away by holding Unicycive Therapeutics and First Wave BioPharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on First Wave BioPharma and Unicycive Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Unicycive Therapeutics are associated (or correlated) with First Wave. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of First Wave BioPharma has no effect on the direction of Unicycive Therapeutics i.e., Unicycive Therapeutics and First Wave go up and down completely randomly.

Pair Corralation between Unicycive Therapeutics and First Wave

If you would invest  69.00  in Unicycive Therapeutics on October 6, 2024 and sell it today you would earn a total of  10.00  from holding Unicycive Therapeutics or generate 14.49% return on investment over 90 days.
Time Period3 Months [change]
DirectionFlat 
StrengthInsignificant
Accuracy5.0%
ValuesDaily Returns

Unicycive Therapeutics  vs.  First Wave BioPharma

 Performance 
       Timeline  
Unicycive Therapeutics 

Risk-Adjusted Performance

19 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Unicycive Therapeutics are ranked lower than 19 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak fundamental indicators, Unicycive Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.
First Wave BioPharma 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days First Wave BioPharma has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong fundamental drivers, First Wave is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders.

Unicycive Therapeutics and First Wave Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Unicycive Therapeutics and First Wave

The main advantage of trading using opposite Unicycive Therapeutics and First Wave positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Unicycive Therapeutics position performs unexpectedly, First Wave can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in First Wave will offset losses from the drop in First Wave's long position.
The idea behind Unicycive Therapeutics and First Wave BioPharma pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.

Other Complementary Tools

Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Bonds Directory
Find actively traded corporate debentures issued by US companies
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum